CASI Pharmaceuticals (NASDAQ:CASI) issued its quarterly earnings data on Wednesday, November 14th. The biotechnology company reported ($0.10) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.04) by ($0.06), Bloomberg Earnings reports.

Shares of NASDAQ:CASI traded down $0.13 during trading hours on Friday, hitting $3.90. 249,673 shares of the company’s stock traded hands, compared to its average volume of 347,006. CASI Pharmaceuticals has a 1 year low of $2.55 and a 1 year high of $8.89. The firm has a market capitalization of $383.53 million, a PE ratio of -21.67 and a beta of 1.46.

CASI has been the topic of several analyst reports. HC Wainwright set a $7.00 price objective on CASI Pharmaceuticals and gave the stock a “buy” rating in a research note on Wednesday, November 21st. ValuEngine lowered CASI Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Friday, September 28th. Finally, BidaskClub upgraded CASI Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday.

TRADEMARK VIOLATION WARNING: “CASI Pharmaceuticals (NASDAQ:CASI) Announces Earnings Results, Misses Estimates By $0.06 EPS” was reported by Marea Informative and is owned by of Marea Informative. If you are viewing this article on another domain, it was illegally copied and republished in violation of international copyright legislation. The correct version of this article can be accessed at

About CASI Pharmaceuticals

CASI Pharmaceuticals, Inc, a biopharmaceutical company, develops therapeutics addressing cancer and other unmet medical needs in China. Its lead drug candidate is ENMD-2076, an Aurora A/angiogenic kinase inhibitor, which is in multiple Phase II studies in advanced fibrolamellar carcinoma and triple-negative breast cancer.

Further Reading: Capital gains and your 401(k) or IRA

Earnings History for CASI Pharmaceuticals (NASDAQ:CASI)

Receive News & Ratings for CASI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CASI Pharmaceuticals and related companies with's FREE daily email newsletter.